. Author manuscript; available in PMC: 2014 Feb 13.

Published in final edited form as: Pharmacogenet Genomics. 2013 Feb;23(2):69–77. doi: 10.1097/FPC.0b013e32835ca260

Table 3.

Genetic variants that reached q-value < 0.25 with treatment response in CATIE GWAS and also reached nominal significant association with a global impression score (p-value < 0.05). We only considered patients under the same antipsychotic treatment.

GWAS Result							Secondary Association		Correlation^b
Study	Antipsychotic	Phenotype	SNP	Gene	p-value	q-value	Phenotype	p-value
Current	Risperidone	CGI-S	rs8050896		3.85E-08	0.019	PGI	0.009	0.18
	Risperidone	PGI	rs785423	TJP1	4.86E-07	0.081	CGI-S	0.024	0.18
	Olanzapine	CGI-S	rs6688363	ATP1A2	1.59E-07	0.078	PGI	0.019	0.38
	Olanzapine	PGI	rs10170310	SPOPL	1.03E-07	0.051	CGI-S	0.009	0.38
McClay et al. 2011^c	Risperidone	PANSS^a negative	rs17727261	CNTNAP5	5.41E-07	0.134	PGI	0.034	0.19
McClay et al. 2011^c	Risperidone	PANSS^a negative	rs17727261	CNTNAP5	5.41E-07	0.134	CGI-S	0.002	−0.08
McClay et al. 2011^d	Olanzapine	Working memory	rs11214606	DRD2	4.84E-07	0.081	PGI	0.018	0.13
	Quetiapine	Working memory	rs6856328	LPHN3	8.26E-07	0.133	PGI	0.010	−0.10
	Quetiapine	Working memory	rs16865258	CLDN1	1.74E-06	0.169	CGI-S	0.029	−0.09

PANSS – Positive and Negative Syndrome Scale.

Correlation of treatment effect estimates.

McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry. 2011;16(1):76–85.

McClay JL, Adkins DE, Aberg K, Bukszar J, Khachane AN, Keefe RS, et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology. 2011;36(3):616–26.